Alvotech Receives FDA BLA Acceptance For AVT16, A Proposed Interchangeable Biosimilar To Vedolizumab, Under Teva Commercialization Partnership

Loading news article.

Alvotech Receives FDA BLA Acceptance For AVT16, A Proposed Interchangeable Biosimilar To Vedolizumab, Under Teva Commercialization Partnership | WAPE

Article summary